Home Page

2019 Voxmedia HFSA Pgm Image

Reducing Cardiovascular Risk and
Renal Risk With SGLT2 Inhibitors:
Exploring the Evidence

Sunday,September 15, 2019

Symposium: 6:30PM - 8:00PM

Venue:  Pennsylvania Convention Center
              Room 201 A/B
              1101 Arch Street
              Philadelphia, Pennsylvania

Faculty: Mikhail Kosiborod, MD(Chair);
               George Bakris, MD;
               Robert Mentz, MD.

Registration for this program is now closed.

Note:This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Accredited Sponsor:

Program Overview:

Diabetes and heart failure (HF) often occur concomitantly, and each disease independently increases the risk for the other. Observational studies have consistently demonstrated a 2- to 4-fold increased risk of HF in individuals with diabetes compared with those without diabetes. Diabetes can contribute to the development of structural heart disease and HF via systemic, myocardial, and cellular mechanisms. Support for the bidirectional association of HF and diabetes is provided by knowledge that metabolic impairment is intrinsic to HF pathophysiology, insulin resistance is present in up to 60% of patients with HF, and nondiabetic patients with HF enrolled in HF trials have an incidence of diabetes that is substantially higher than adults of similar age in the general population. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated reductions in the risk for major cardiovascular events, HF-related outcomes, and renal endpoints. This emerging evidence for reductions in cardiovascular, HF, and renal risk has resulted in landmark publications by the ACC, and by the AHA with the HFSA. The ACC has developed the 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease (ASCVD), which provides guidance for cardiovascular clinicians on the use of SGLT2 inhibitors, as well as glucagon-like peptide 1 receptor agonists (GLP-1 RAs), for reducing cardiovascular risk in patients with type 2 diabetes and established ASCVD. In addition, the AHA and HFSA have published a scientific statement on Type 2 Diabetes Mellitus and Heart Failure, which indicates the preferred use of SGLT2 inhibitors with metformin in patients at high risk for HF and those with established HF. In this program, expert faculty members will discuss the intertwined relationship between diabetes and HF, explain clinical trial data with SGLT2 inhibitors on cardiovascular, HF, and renal outcomes, and describe best practices for incorporating SGLT2 inhibitors into patient management.

Educational Objectives: 
Upon completion of this activity, attendees should be able to:

  • Discuss the relationships between diabetes and cardiovascular disease, heart failure, and chronic kidney disease.
  • Interpret cardiovascular, heart failure and renal outcomes with SGLT2 inhibitors.
  • Demonstrate best practices for utilizing SGLT2 inhibitors in patients with ASCVD, HF, and CKD.

Target Audience: This educational activity is intended for cardiologists and other healthcare professionals involved in the management of patients with heart failure.

Educational Grant: This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Eligibility Statement: Registration for the 23rd Annual Scientific Meeting and an official name badge are required to attend this symposium.

Privacy Policy
VOXMEDIA does not collect, use, sell or license personal information. Representations of User: By registering for this program and using the website, you hereby represent and warrant that: (i) all information contained in any information submitted by you is either owned by you or rights have been granted to you permitting you to disseminate the information as set forth in these Terms and Conditions; and (ii) the information contained in any submissions by you does not infringe on the intellectual property rights of others, including but not limited to, copyright, trademark, patent, or trade secret rights.

Accreditation and Credit Designation Statements:
Physicians: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: See onsite meeting materials for credit information. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.

Disclosure Statement:
It is the policy of Heart Failure Society of America to ensure the unbiased, fair-balanced and scientifically rigorous nature of all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial or other interest or relationship (1) with the manufacturer(s) of any commercial product(s), device(s) or service(s) AND (2) with any commercial supporters of an activity prior to participating in the planning of an activity, contributing to content, or making a presentation. Only then will faculty receive approval to participate. Faculty are expected to contribute evidence-based materials and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information is peer-reviewed.

Americans with Disabilities Act Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 454 Morris Avenue, Springfield, New Jersey 07081 USA; Phone: 973-467-0500.